NASDAQ:FPRX - Five Prime Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$38.00
+0 (0.00%)
Get New Five Prime Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FPRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Five Prime Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $38.00.

This chart shows the closing price for FPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Five Prime Therapeutics. This rating has held steady since March 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2021GuggenheimReiterated RatingBuy ➝ Neutral$38.00N/A
3/10/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$38.00N/A
3/8/2021GuggenheimDowngradeBuy ➝ Neutral$38.00Low
3/4/2021Roth CapitalDowngradeBuy ➝ NeutralLow
3/4/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$38.00Low
3/4/2021WedbushDowngradeOutperform ➝ NeutralHigh
3/4/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal WeightHigh
11/11/2020WedbushBoost Price Target$9.00 ➝ $28.00High
11/11/2020SVB LeerinkReiterated RatingOutperform$9.00 ➝ $33.00High
11/11/2020Roth CapitalUpgradeNeutral ➝ Buy$9.00 ➝ $30.00High
11/11/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$34.00High
11/11/2020JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$14.00High
11/4/2020SVB LeerinkLower Price TargetOutperform$11.00 ➝ $9.00High
9/22/2020GuggenheimUpgradeNeutral ➝ Buy$11.00High
8/12/2020CowenReiterated RatingOutperformHigh
6/22/2020WedbushUpgradeNeutral ➝ Outperform$5.00 ➝ $9.00High
2/28/2020JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
2/18/2020WedbushDowngradeOutperform ➝ Neutral$12.00 ➝ $5.00Low
11/20/2019GuggenheimInitiated CoverageHoldHigh
11/7/2019CowenReiterated RatingBuyLow
9/30/2019GuggenheimDowngradeBuy ➝ NeutralHigh
6/3/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$35.00 ➝ $10.00High
5/29/2019Roth CapitalInitiated CoverageNeutral ➝ Neutral$10.00 ➝ $10.00Medium
4/12/2019GuggenheimInitiated CoverageBuy$24.00High
2/27/2019CowenReiterated RatingBuyHigh
1/17/2019WedbushUpgradeNeutral ➝ Outperform$16.00High
9/13/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$24.00High
8/20/2018CitigroupLower Price TargetBuy ➝ Buy$60.00 ➝ $44.00Low
8/10/2018WedbushBoost Price TargetNeutral ➝ Hold$17.00 ➝ $19.00High
8/9/2018Wells Fargo & CompanyLower Price TargetOutperform$58.00 ➝ $35.00High
6/28/2018Raymond JamesInitiated CoverageMarket PerformHigh
6/15/2018JPMorgan Chase & Co.Initiated CoverageNeutral$19.00High
5/17/2018WedbushInitiated CoverageNeutral$17.00Low
5/10/2018The Goldman Sachs GroupInitiated CoverageNeutral$20.00Medium
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$75.00 ➝ $60.00Low
2/28/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$94.00 ➝ $25.00High
11/7/2017BMO Capital MarketsBoost Price TargetOutperform$71.00 ➝ $75.00N/A
11/6/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$41.00 ➝ $50.00N/A
10/25/2017Royal Bank of CanadaReiterated RatingBuy$41.00N/A
10/16/2017BMO Capital MarketsUpgradeMarket Perform ➝ OutperformN/A
9/22/2017BMO Capital MarketsReiterated RatingHold$39.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$41.00High
9/12/2017Jefferies Financial GroupReiterated RatingBuy$52.00High
8/10/2017Jefferies Financial GroupReiterated RatingBuy$55.00 ➝ $52.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Five Prime Therapeutics logo
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $38.00
Low: $38.00
High: $38.00

50 Day Range

MA: $37.94
Low: $37.65
High: $38.00

52 Week Range

Now: $38.00
Low: $2.61
High: $38.90

Volume

N/A

Average Volume

1,981,352 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Five Prime Therapeutics?

The following sell-side analysts have issued research reports on Five Prime Therapeutics in the last twelve months: StockNews.com.
View the latest analyst ratings for FPRX.

What is the current price target for Five Prime Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Five Prime Therapeutics in the last year.
View the latest price targets for FPRX.

What is the current consensus analyst rating for Five Prime Therapeutics?

Five Prime Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FPRX.

How do I contact Five Prime Therapeutics' investor relations team?

Five Prime Therapeutics' physical mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company's listed phone number is 415-365-5600 and its investor relations email address is [email protected] The official website for Five Prime Therapeutics is www.fiveprime.com. Learn More about contacing Five Prime Therapeutics investor relations.